Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Magnetic Marker Monitoring of Furosemide-containing Gastroretentive Formulation in Healthy Male Subjects (Fasting and Fed Conditions)

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
LTS Lohmann Therapie-Systeme AG
ClinicalTrials.gov Identifier:
NCT01887379
First received: June 24, 2013
Last updated: December 11, 2013
Last verified: December 2013
  Purpose

Furosemide is a diuretic drug, used in the treatment of oedematous states associated with cardiac, renal, and hepatic disorder, and may be effective in patients unresponsive to thiazide diuretics. Furosemide is also used in the treatment of hypertension.

Absorption of furosemide from the gastrointestinal tract is fairly rapid; bioavailability is 60-70%, but variable and not predictable, with large intra- and inter-individual variability, and are influenced by dosage form, underlying diseases, and by the presence of food after oral administration. Data from animal model show that furosemide administered into the stomach is more rapidly absorbed than if is administered into the small intestine.

To increase the residency of furosemide in the stomach after oral administration, a gastroretentive dosage form (GRDF) of furosemide has been developed. In the current study, the new formulation (30mg furosemide coated tablet) will be tested in healthy male subjects. Absorption will be characterised by an effective and safe imaging technique - Magnetic Marker Monitoring (MMM), based on Fe3O4 added to the drug product to generate magnetic signal that can be used for up to 12 h after furosemide administration to localize the medication in the gastrointestinal tract. Fe3O4 is frequently used as colouring pigment in medicinal products. It does not exhibit own pharmacodynamic activity and is considered as an inactive ingredient.

In the current study, GRDF formulation of furosemide will be evaluated for: gastric residence as well as pharmacokinetic and pharmacodynamic characteristics under fasting and fed conditions. As part of the study, the subjects will be hospitalized for 1 day during each drug administration. The duration of the stay will depend on the intestinal behaviour of the investigational product.


Condition Intervention Phase
Gastroretentive Drug Formulation of Furosemide
Oedema
Drug: GRDF furosemide
Phase 1

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Pharmacokinetics/Dynamics Study
Intervention Model: Crossover Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Characterisation of Gastric Residence of a Furosemide-containing New Gastric Retention System by Means of MMM Measurement and Determination of Pharmacokinetics, Pharmacodynamics and Safety

Resource links provided by NLM:


Further study details as provided by LTS Lohmann Therapie-Systeme AG:

Primary Outcome Measures:
  • Residency time of GRDF furosemide in the gastrointestinal tract, evaluated with MMM technique, under fasted and fed conditions. [ Time Frame: every 30 min for up to 12 h after drug administration; maximal observation time 12 h ] [ Designated as safety issue: No ]

    Residency time of GRDF furosemide in the gastrointestinal track will be monitored using the non-invasive MMM technique under fasted and fed conditions. Measurements will start after each administration and last until 2 hours after gastric emptying indicated by the MMM measurement, but not longer than 12 h post administration. Each observation interval for each subject will last for a minimum of 10 min followed by a break of maximum 20 min. For meal intake, a break of the MMM measuring of 30 minutes will be performed.

    Anatomical localisation within the measuring sequences will be listed for each subject and treatment

    Statistical evaluation of gastric emptying time will include: arithmetic means, medians, minimum , maximum, standard deviation.

    GRDF=Gastro retentive dosage formulation



Secondary Outcome Measures:
  • Cmax of GRDF furosemide under fasted conditions [ Time Frame: pre-dose (within 1 h prior to drug administration) and 0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 10, 12, and 24 h after drug administration. ] [ Designated as safety issue: No ]

    Characterization of the pharmacokinetic (PK) properties of GRDF furosemide, with special focus on the absorption phase of furosemide. Compare results during fasted and fed state.

    Blood samples for the determination of furosemide concentration will be taken at pre-dose (within 1 h prior to administration) and 0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 10, 12, and 24 h after administration.

    LC-MS/MS will be used to analyze furosemide in plasma.

    Cmax = maximum concentration in plasma; GRDF=Gastro retentive dosage formulation


  • Cmax of GRDF furosemide under fed conditions [ Time Frame: pre-dose (within 1 h prior to drug administration) and 0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 10, 12, and 24 h after drug administration. ] [ Designated as safety issue: No ]

    Characterization of the pharmacokinetic (PK) properties of GRDF furosemide, with special focus on the absorption phase of furosemide. Compare results during fasted and fed state.

    Blood samples for the determination of furosemide concentration will be taken at pre-dose (within 1 h prior to administration) and 0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 10, 12, and 24 h after administration.

    LC-MS/MS will be used to analyze furosemide in plasma.

    Cmax = maximum concentration in plasma; GRDF=Gastro retentive dosage formulation


  • tmax of GRDF furosemide under fasted conditions [ Time Frame: pre-dose (within 1 h prior to drug administration) and 0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 10, 12, and 24 h after drug administration. ] [ Designated as safety issue: No ]

    Characterization of the pharmacokinetic (PK) properties of GRDF furosemide, with special focus on the absorption phase of furosemide. Compare results during fasted and fed state.

    Blood samples for the determination of furosemide concentration will be taken at pre-dose (within 1 h prior to administration) and 0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 10, 12, and 24 h after administration.

    LC-MS/MS will be used to analyze furosemide in plasma.

    tmax = time to reach maximum concentration in plasma; GRDF=Gastro retentive dosage formulation


  • tmax of GRDF furosemide under fed conditions [ Time Frame: pre-dose (within 1 h prior to drug administration) and 0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 10, 12, and 24 h after drug administration. ] [ Designated as safety issue: No ]

    Characterization of the pharmacokinetic (PK) properties of GRDF furosemide, with special focus on the absorption phase of furosemide. Compare results during fasted and fed state.

    Blood samples for the determination of furosemide concentration will be taken at pre-dose (within 1 h prior to administration) and 0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 10, 12, and 24 h after administration.

    LC-MS/MS will be used to analyze furosemide in plasma.

    tmax = time to reach maximum concentration in plasma; GRDF=Gastro retentive dosage formulation


  • t1/2 of GRDF furosemide under fasted conditions [ Time Frame: pre-dose (within 1 h prior to drug administration) and 0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 10, 12, and 24 h after drug administration. ] [ Designated as safety issue: No ]

    Characterization of the pharmacokinetic (PK) properties of GRDF furosemide, with special focus on the absorption phase of furosemide. Compare results during fasted and fed state.

    Blood samples for the determination of furosemide concentration will be taken at pre-dose (within 1 h prior to administration) and 0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 10, 12, and 24 h after administration.

    LC-MS/MS will be used to analyze furosemide in plasma.

    t1/2 = apparent terminal elimination half-life; GRDF=Gastro retentive dosage formulation


  • t1/2 of GRDF furosemide under fed conditions [ Time Frame: pre-dose (within 1 h prior to drug administration) and 0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 10, 12, and 24 h after drug administration. ] [ Designated as safety issue: No ]

    Characterization of the pharmacokinetic (PK) properties of GRDF furosemide, with special focus on the absorption phase of furosemide. Compare results during fasted and fed state.

    Blood samples for the determination of furosemide concentration will be taken at pre-dose (within 1 h prior to administration) and 0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 10, 12, and 24 h after administration.

    LC-MS/MS will be used to analyze furosemide in plasma.

    t1/2 = apparent terminal elimination half-life; GRDF=Gastro retentive dosage formulation


  • AUC0-tlast of GRDF furosemide under fasted conditions [ Time Frame: pre-dose (within 1 h prior to drug administration) and 0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 10, 12, and 24 h after drug administration. ] [ Designated as safety issue: No ]

    Characterization of the pharmacokinetic (PK) properties of GRDF furosemide, with special focus on the absorption phase of furosemide. Compare results during fasted and fed state.

    Blood samples for the determination of furosemide concentration will be taken at pre-dose (within 1 h prior to administration) and 0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 10, 12, and 24 h after administration.

    LC-MS/MS will be used to analyze furosemide in plasma.

    AUC0 = area under the plasma concentration vs. time curve from dosing time to the last measurement time point with a concentration value above the lower limit of quantitation, calculated by means of the linear up/log down method (linear trapezoidal rule for increases in concentration/logarithmic trapezoidal rule for decreases in concentrations; GRDF=Gastro retentive dosage formulation


  • AUC0-tlast of GRDF furosemide under fed conditions [ Time Frame: pre-dose (within 1 h prior to drug administration) and 0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 10, 12, and 24 h after drug administration. ] [ Designated as safety issue: No ]

    Characterization of the pharmacokinetic (PK) properties of GRDF furosemide, with special focus on the absorption phase of furosemide. Compare results during fasted and fed state.

    Blood samples for the determination of furosemide concentration will be taken at pre-dose (within 1 h prior to administration) and 0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 10, 12, and 24 h after administration.

    LC-MS/MS will be used to analyze furosemide in plasma.

    AUC0-tlast = area under the plasma concentration vs. time curve from dosing time to the last measurement time point with a concentration value above the lower limit of quantitation, calculated by means of the linear up/log down method (linear trapezoidal rule for increases in concentration/logarithmic trapezoidal rule for decreases in concentrations; GRDF=Gastro retentive dosage formulation


  • AUC 0-infinity of GRDF furosemide under fasted conditions [ Time Frame: pre-dose (within 1 h prior to drug administration) and 0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 10, 12, and 24 h after drug administration. ] [ Designated as safety issue: No ]

    Characterization of the pharmacokinetic (PK) properties of GRDF furosemide, with special focus on the absorption phase of furosemide. Compare results during fasted and fed state.

    Blood samples for the determination of furosemide concentration will be taken at pre-dose (within 1 h prior to administration) and 0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 10, 12, and 24 h after administration.

    LC-MS/MS will be used to analyze furosemide in plasma.

    AUC0-infinity = AUC0-tlast + AUCexpol; GRDF=Gastro retentive dosage formulation


  • AUC 0-infinity of GRDF furosemide under fed conditions [ Time Frame: pre-dose (within 1 h prior to drug administration) and 0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 10, 12, and 24 h after drug administration. ] [ Designated as safety issue: No ]

    Characterization of the pharmacokinetic (PK) properties of GRDF furosemide, with special focus on the absorption phase of furosemide. Compare results during fasted and fed state.

    Blood samples for the determination of furosemide concentration will be taken at pre-dose (within 1 h prior to administration) and 0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 10, 12, and 24 h after administration.

    LC-MS/MS will be used to analyze furosemide in plasma.

    AUC0-infinity = AUC0-tlast + AUCexpol; GRDF=Gastro retentive dosage formulation


  • AUCextrapol of GRDF furosemide under fasted conditions [ Time Frame: pre-dose (within 1 h prior to drug administration) and 0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 10, 12, and 24 h after drug administration. ] [ Designated as safety issue: No ]

    Characterization of the pharmacokinetic (PK) properties of GRDF furosemide, with special focus on the absorption phase of furosemide. Compare results during fasted and fed state.

    Blood samples for the determination of furosemide concentration will be taken at pre-dose (within 1 h prior to administration) and 0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 10, 12, and 24 h after administration.

    LC-MS/MS will be used to analyze furosemide in plasma.

    AUCextrapol = AUCextrapolated = Clast/lamda; lamda = apparent terminal elimination rate constant determined by log-linear regression; GRDF=Gastro retentive dosage formulation


  • AUCextrapol of GRDF furosemide under fed conditions [ Time Frame: pre-dose (within 1 h prior to drug administration) and 0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 10, 12, and 24 h after drug administration. ] [ Designated as safety issue: No ]

    Characterization of the pharmacokinetic (PK) properties of GRDF furosemide, with special focus on the absorption phase of furosemide. Compare results during fasted and fed state.

    Blood samples for the determination of furosemide concentration will be taken at pre-dose (within 1 h prior to administration) and 0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 10, 12, and 24 h after administration.

    LC-MS/MS will be used to analyze furosemide in plasma.

    AUCextrapol = AUCextrapolated = Clast/lamda; lamda = apparent terminal elimination rate constant determined by log-linear regression; GRDF=Gastro retentive dosage formulation


  • CL_f of GRDF furosemide under fasted conditions [ Time Frame: pre-dose (within 1 h prior to drug administration) and 0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 10, 12, and 24 h after drug administration. ] [ Designated as safety issue: No ]

    Characterization of the pharmacodynamic properties of GRDF furosemide, with special focus on the absorption phase of furosemide. Compare results during fasted and fed state.

    Blood samples for the determination of furosemide concentration will be taken at pre-dose (within 1 h prior to administration) and 0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 10, 12, and 24 h after administration.

    LC-MS/MS will be used to analyze furosemide in plasma.

    CL_f = apparent total body clearance of furosemide: dose / AUC0-∞; GRDF=Gastro retentive dosage formulation


  • CL_f of GRDF furosemide under fed conditions [ Time Frame: pre-dose (within 1 h prior to drug administration) and 0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 10, 12, and 24 h after drug administration. ] [ Designated as safety issue: No ]

    Characterization of the pharmacodynamic properties of GRDF furosemide, with special focus on the absorption phase of furosemide. Compare results during fasted and fed state.

    Blood samples for the determination of furosemide concentration will be taken at pre-dose (within 1 h prior to administration) and 0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 10, 12, and 24 h after administration.

    LC-MS/MS will be used to analyze furosemide in plasma.

    CL_f = apparent total body clearance of furosemide: dose / AUC0-∞; GRDF=Gastro retentive dosage formulation


  • Vdz of GRDF furosemide under fasted conditions [ Time Frame: pre-dose (within 1 h prior to drug administration) and 0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 10, 12, and 24 h after drug administration. ] [ Designated as safety issue: No ]

    Characterization of the pharmacodynamic properties of GRDF furosemide, with special focus on the absorption phase of furosemide. Compare results during fasted and fed state.

    Blood samples for the determination of furosemide concentration will be taken at pre-dose (within 1 h prior to administration) and 0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 10, 12, and 24 h after administration.

    LC-MS/MS will be used to analyze furosemide in plasma.

    Vdz = apparent volume of distribution of furosemide: dose / (AUC0-∞ x λ); GRDF=Gastro retentive dosage formulation; λ=apparent terminal elimination rate constant determined by log-linear regression


  • Vdz of GRDF furosemide under fed conditions [ Time Frame: pre-dose (within 1 h prior to drug administration) and 0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 10, 12, and 24 h after drug administration. ] [ Designated as safety issue: No ]

    Characterization of the pharmacodynamic properties of GRDF furosemide, with special focus on the absorption phase of furosemide. Compare results during fasted and fed state.

    Blood samples for the determination of furosemide concentration will be taken at pre-dose (within 1 h prior to administration) and 0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 10, 12, and 24 h after administration.

    LC-MS/MS will be used to analyze furosemide in plasma.

    Vdz = apparent volume of distribution of furosemide: dose / (AUC0-∞ x λ); GRDF=Gastro retentive dosage formulation; λ=apparent terminal elimination rate constant determined by log-linear regression


  • Sodium excretion over time under fasted conditions [ Time Frame: pre-dose (within 1 hour prior to administration), 0-2h, 2-4h, 4-8h, and 8-12h after administration. ] [ Designated as safety issue: No ]
    Sodium in urine will be measured for each time interval and total sampling time. Urine will be collected and sampled during the following sample intervals: pre-dose (within 1 hour prior to administration), 0-2h, 2-4h, 4-8h, and 8-12h after administration.

  • Sodium excretion over time under fed conditions [ Time Frame: pre-dose (within 1 hour prior to administration), 0-2h, 2-4h, 4-8h, and 8-12h after administration. ] [ Designated as safety issue: No ]
    Sodium in urine will be measured for each time interval and total sampling time. Urine will be collected and sampled during the following sample intervals: pre-dose (within 1 hour prior to administration), 0-2h, 2-4h, 4-8h, and 8-12h after administration.

  • Urine excretion over time under fasted conditions [ Time Frame: pre-dose (within 1 hour prior to administration), 0-2h, 2-4h, 4-8h, and 8-12h after administration. ] [ Designated as safety issue: No ]
    Urine volume will be measured for each time interval and total sampling time. Urine will be collected and sampled during the following sample intervals: pre-dose (within 1 hour prior to administration), 0-2h, 2-4h, 4-8h, and 8-12h after administration.

  • Urine excretion over time under fed conditions [ Time Frame: pre-dose (within 1 hour prior to administration), 0-2h, 2-4h, 4-8h, and 8-12h after administration. ] [ Designated as safety issue: No ]
    Urine volume will be measured for each time interval and total sampling time. Urine will be collected and sampled during the following sample intervals: pre-dose (within 1 hour prior to administration), 0-2h, 2-4h, 4-8h, and 8-12h after administration.


Enrollment: 10
Study Start Date: June 2013
Study Completion Date: August 2013
Primary Completion Date: August 2013 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: GRDF furosemide fasting conditions
Subjects will be tested under fasting conditions after administration of GRDF Furosemide.
Drug: GRDF furosemide
The GRDF furosemide tablet contains Fe3O4, which serves as an inactive magnetic marker to allow monitoring of the tablet transit through the gastrointestinal tract, using the MMM imaging technique.
Other Name: GRDF furosemide is a gastro retentive dosage form of furesomide
Experimental: GRDF furosemide fed conditions
Subjects will be tested under fed conditions after administration of GRDF Furosemide.
Drug: GRDF furosemide
The GRDF furosemide tablet contains Fe3O4, which serves as an inactive magnetic marker to allow monitoring of the tablet transit through the gastrointestinal tract, using the MMM imaging technique.
Other Name: GRDF furosemide is a gastro retentive dosage form of furesomide

Detailed Description:

Furosemide is a diuretic drug, widely used in the treatment of oedematous states associated with cardiac, renal, and hepatic disorder, and may be effective in patients unresponsive to thiazide diuretics. Furosemide is also used in the treatment of hypertension.

Absorption of furosemide from the gastrointestinal tract is fairly rapid. Bioavailability is reported as 60-70%, but is variable and not predictable. The rate and extent of absorption show a large intra- and inter-individual variability and are influenced by dosage form, underlying diseases, and by the presence of food after oral administration. Results obtained with an animal model indicate that furosemide administered into the stomach is more rapidly absorbed than if is is administered into the small intestine.

To increase the residency of furosemide in the stomach after oral administration, a gastroretentive dosage form (GRDF) of furosemide has been developed. In this study, the new formulation(30mg furosemide coated tablet) will be tested in healthy male subjects. Absorption will be characterised by imaging technique - Magnetic Marker Monitoring (MMM), which is the most effective and safe imaging technique currently available. MMM is based on a iron-III-oxide (Fe3O4) added to the drug product to generate magnetic signal that can be used to localize the administered medication in the gastrointestinal tract.

Fe3O4 is frequently used as colouring pigment in medicinal products. It does not exhibit own pharmacodynamic activity and thus, it is considered as clinically inactive ingredient. Fe3O4 exhibits a dipole moment and thus, after magnetisation of solid oral dosage forms containing homogenously distributed Fe3O4, the product generates a magnetic signal, which can be used for localisation of the dosage form in the gastrointestinal tract by Magnetic Marker Monitoring technique.

The aim of the current study is to evaluate the GRDF formulation of furosemide for: gastric residence, pharmacokinetic and pharmacodynamic characteristics under fasting and fed conditions. As part of the study, the subjects will be hospitalized for 1 day during each drug administration (i.e. a total of two days). The duration of the stay will depend on the intestinal behaviour of the investigational product. The MMM monitoring be performed for up to 12 h after furosemide administration. For pharmacokinetic determinations, liquid chromatography coupled with tandem mass spectrometry (LC-MS/MS) will be used to analyze furosemide in plasma.

  Eligibility

Ages Eligible for Study:   18 Years to 55 Years
Genders Eligible for Study:   Male
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  1. sex: male
  2. ethnic origin: Caucasian
  3. age: 18 years to 55 years
  4. body-mass index (BMI): > or = 19 kg/m² and < or = 27 kg/m²
  5. good state of health
  6. non-smoker or ex-smoker for at least 1 month
  7. written informed consent, after having been informed about benefits and potential risks of the clinical trial, as well as details of the insurance taken out to cover the subjects participating in the clinical trial

Exclusion Criteria:

  1. existing cardiac and/or haematological diseases or pathological findings, which might interfere with the safety or tolerability of the active ingredient
  2. existing hepatic and/or renal diseases or pathological findings, which might interfere with the safety or tolerability of the active ingredient
  3. existing gastrointestinal diseases or pathological findings, which might interfere with the safety and tolerability or with gastric emptying and the gastrointestinal transport (e.g. inflammatory bowel diseases, ileus)
  4. history of relevant central nervous system (CNS) and/or psychiatric disorders and/or currently treated CNS and/or psychiatric disorders
  5. any surgery at the gastrointestinal tract, which might interfere with the safety of the test product or any stomach reduction like Bioenterics Intragastric Balloon (BIB) or gastric banding
  6. known allergic reactions to the active ingredients used or to constituents of the pharmaceutical preparations
  7. known allergic reactions to sulphonamide
  8. subjects with severe allergies or multiple drug allergies unless it is judged as not relevant for the clinical trial by the investigator
  9. heart rate < 50 bpm or > 90 bpm
  10. systolic blood pressure of < 100 mmHg and > 140 mmHg, diastolic blood pressure of < 60 mmHg and >90 mmHg
  11. laboratory values, especially for sodium, potassium, calcium, creatinine, urea, uric acid, and blood glucose out of normal range unless the deviation from normal is judged as not relevant for the clinical trial by the investigator
  12. positive anti-human immunodeficiency virus-test (if positive to be verified by western blot), surface antigen of the hepatitis B virus (HBs-AG)test [if positive to be verified by test for hepatitis B Core (HBc-IgM)] or anti-hepatitis C virus-test
  13. renal failure with anuria
  14. coma and praecoma hepatica
  15. severe hypokalemia and/or hyponatremia
  16. hypovolemia or dehydration
  17. subjects with manifest or latent diabetes mellitus or gout
  18. subjects with cerebrovascular insufficiency or coronary heart disease
  19. subjects with bladder outlet obstruction (BOO) e.g. prostatic hypertrophy, hydronephrosis or ureteral stenosis
  20. hypoproteinemia
  21. liver cirrhosis and simultaneous limitation of kidney function
  22. acute or chronic diseases which could affect gastric emptying and the gastrointestinal transport
  23. history of or current drug or alcohol dependence
  24. positive alcohol or drug test at screening examination
  25. regular intake of alcoholic food or beverages of ≥ 40 g pure ethanol for male per day
  26. subjects who are on a diet which could affect gastric emptying and the gastro-intestinal transport
  27. regular intake of caffeine containing food or beverages of ≥ 500 mg caffeine per day
  28. subjects with claustrophobia
  29. ferromagnetic implants or any other magnetic disturbance, which can affect the Magnetic Marker Monitoring measurement
  30. blood donation or other blood loss of more than 400 ml within the last two months prior to individual enrolment of the subject
  31. participation in a clinical trial during the last two months prior to individual enrolment of the subject
  32. regular treatment with any systemically available medication including all ototoxic medication like aminoglycosides and medication which could affect gastric emptying and the gastrointestinal transport (e.g. laxatives, metoclopramide, loperamide, antacids, H2-receptor antagonists) or antibiotics
  33. subjects, who report a frequent occurrence of migraine attacks
  34. subjects suspected or known not to follow instructions
  35. subjects who are unable to understand the written and verbal instructions, in particular regarding the risks and inconveniences they will be exposed to during their participation in the clinical trial
  36. subjects who have forfeited their own freedom by administrative or legal award, or who are under guardianship or have been admitted in a sanitary or social institution
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01887379

Locations
Germany
SocraTec R&D GmbH Clinical Pharmacology Unit
Berlin, Germany, 10578
Sponsors and Collaborators
LTS Lohmann Therapie-Systeme AG
Investigators
Principal Investigator: Frank Donath, MD SocraTec R&D GmbH, Clinical Pharmacology Unit
  More Information

No publications provided

Responsible Party: LTS Lohmann Therapie-Systeme AG
ClinicalTrials.gov Identifier: NCT01887379     History of Changes
Other Study ID Numbers: LTS 03/10, 2013-001063-23
Study First Received: June 24, 2013
Last Updated: December 11, 2013
Health Authority: Germany: Federal Institute for Drugs and Medical Devices

Keywords provided by LTS Lohmann Therapie-Systeme AG:
Gastroretentive drug formulation
Furosemide
Magnetic Marker Monitoring
Magnetic marker
Oedema

Additional relevant MeSH terms:
Furosemide
Cardiovascular Agents
Diuretics
Membrane Transport Modulators
Molecular Mechanisms of Pharmacological Action
Natriuretic Agents
Pharmacologic Actions
Physiological Effects of Drugs
Sodium Potassium Chloride Symporter Inhibitors
Therapeutic Uses

ClinicalTrials.gov processed this record on November 24, 2014